Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Survival Improvement of Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Care 1995 - 2017

Rudolf Weide, Prof., Stefan Feiten, Geothy Chakupurakal, MBBS, MRCPath, PhD, Vera Friesenhahn, Kristina Kleboth, Hubert Köppler, Prof., Julia Lutschkin, Jörg Thomalla, MD, Christoph van Roye, MD, Jochen Heymanns, MD

Blood (2018) 132 (Supplement 1): 4823.

https://doi.org/10.1182/blood-2018-99-109862

Published: 2018

Journal Articles

Reality of Care for Patients with Multiple Myeloma 1995-2016. New Drugs in Routine Care Lead to Improved Survival

Rudolf Weide, Prof., Stefan Feiten, Geothy Chakupurakal, MBBS, MRCPath, PhD, Vera Friesenhahn, Kristina Kleboth, Julia Lutschkin, Jörg Thomalla, MD, Christoph van Roye, MD, Jochen Heymanns, MD

Blood (2017) 130 (Supplement 1): 5628.

https://doi.org/10.1182/blood.V130.Suppl_1.5628.5628

Published: 2017

Journal Articles

Survival Improvement of Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Care. a Retrospective Analysis of All Patients with CLL Who Were Treated in an Oncology Group Practice in Germany Between 1995-2015

Rudolf Weide, Prof., Stefan Feiten, Geothy Chakupurakal, MBBS, MRCPath, PhD, Vera Friesenhahn, Kristina Kleboth, Julia Lutschkin, Jörg Thomalla, MD, Christoph van Roye, MD, Jochen Heymanns, MD, Hubert Köppler, Prof.

Blood (2016) 128 (22): 5961.

https://doi.org/10.1182/blood.V128.22.5961.5961

Published: 2016

Journal Articles

Treatment Reality of Patients with Immune Thrombocytopenia (ITP) in Routine Care

Rudolf Weide, MD, Stefan Feiten, Vera Friesenhahn, Jochen Heymanns, MD, Kristina Kleboth, Jörg Thomalla, MD, Christoph van Roye, MD, Hubert Köppler, Prof. Dr.

Blood (2014) 124 (21): 5009.

https://doi.org/10.1182/blood.V124.21.5009.5009

Published: 2014

Journal Articles

Bendamustine + Rituximab-Combinations and R-CHOP Achieve a Major Survival Improvement Of Patients With Follicular Lymphoma In Routine Care

Rudolf Weide, Prof. Dr., Stefan Feiten, Vera Friesenhahn, Jochen Heymanns, MD, Kristina Kleboth, Jörg Thomalla, MD, Christoph van Roye, MD, Hubert Köppler, Prof. Dr.

Blood (2013) 122 (21): 5584.

https://doi.org/10.1182/blood.V122.21.5584.5584

Published: 2013

Journal Articles

Bendamustine and Rituximab Achieve a Major Survival Improvement Of Patients With Morbus Waldenström In Routine Care

Rudolf Weide, Stefan Feiten, Vera Friesenhahn, Jochen Heymanns, MD, Kristina Kleboth, Jörg Thomalla, MD, Christoph van Roye, MD, Hubert Köppler

Blood (2013) 122 (21): 5611.

https://doi.org/10.1182/blood.V122.21.5611.5611

Published: 2013

Journal Articles

Sequential Treatment With Bendamustine, Rituximab, Chlorambucil and Fludarabine Leads To a Major Survival Improvement Of Patients With Chronic Lymphocytic Leukemia (CLL) In Routine Care

Rudolf Weide, Stefan Feiten, Vera Friesenhahn, Jochen Heymanns, MD, Kristina Kleboth, Jörg Thomalla, MD, Christoph van Roye, MD, Hubert Köppler

Blood (2013) 122 (21): 5613.

https://doi.org/10.1182/blood.V122.21.5613.5613

Published: 2013

Journal Articles

Retherapy with Bendamustine-Containing Regimens in Patients with Relapsed/Refractory CLL and Indolent Lymphomas Achieves High Response Rates

Rudolf Weide, Dr., Stefan Feiten, Vera Friesenhahn, Jochen Heymanns, MD, Kristina Kleboth, Jörg Thomalla, MD, Christoph van Roye, MD, Hubert Köppler, Dr.

Blood (2011) 118 (21): 1615.

https://doi.org/10.1182/blood.V118.21.1615.1615

Published: 2011

Journal Articles

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

Rudolf Weide, MD, Georg Hess, MD, Hubert Koeppler, MD, Jochen Heymanns, MD, Joerg Thomalla, MD, Ali Aldaoud, MD, Christoph Losem, MD, Stefan Schmitz, MD, Ursula Haak, MD, Christoph Huber, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, Martin Dreyling, MD

Blood (2006) 108 (11): 2480.

https://doi.org/10.1182/blood.V108.11.2480.2480

Published: 2006

NARROW

Survival Improvement of Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Care 1995 - 2017

Reality of Care for Patients with Multiple Myeloma 1995-2016. New Drugs in Routine Care Lead to Improved Survival

Survival Improvement of Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Care. a Retrospective Analysis of All Patients with CLL Who Were Treated in an Oncology Group Practice in Germany Between 1995-2015

Treatment Reality of Patients with Immune Thrombocytopenia (ITP) in Routine Care

Bendamustine + Rituximab-Combinations and R-CHOP Achieve a Major Survival Improvement Of Patients With Follicular Lymphoma In Routine Care

Bendamustine and Rituximab Achieve a Major Survival Improvement Of Patients With Morbus Waldenström In Routine Care

Sequential Treatment With Bendamustine, Rituximab, Chlorambucil and Fludarabine Leads To a Major Survival Improvement Of Patients With Chronic Lymphocytic Leukemia (CLL) In Routine Care

Retherapy with Bendamustine-Containing Regimens in Patients with Relapsed/Refractory CLL and Indolent Lymphomas Achieves High Response Rates

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only